275 related articles for article (PubMed ID: 8561141)
1. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine.
Sandborn WJ; Tremaine WJ; Lawson GM
Am J Gastroenterol; 1996 Jan; 91(1):37-43. PubMed ID: 8561141
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
Egan LJ; Sandborn WJ; Tremaine WJ
Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
[TBL] [Abstract][Full Text] [Related]
3. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease.
Sandborn WJ
Am J Gastroenterol; 1997 May; 92(5):876-9. PubMed ID: 9149205
[TBL] [Abstract][Full Text] [Related]
4. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
Dejaco C; Gasché C; Reinisch W; Moser G; Novacek G; Tillinger W; Vogelsang H; Gangl A
Wien Klin Wochenschr; 1998 Sep; 110(16):579-84. PubMed ID: 9782579
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children.
Mahdi G; Israel DM; Hassall E
Am J Gastroenterol; 1996 Jul; 91(7):1355-9. PubMed ID: 8677994
[TBL] [Abstract][Full Text] [Related]
6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
7. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF
Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045
[TBL] [Abstract][Full Text] [Related]
8. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease.
Hermida-Rodriguez C; Cantero Perona J; Garcia-Valriberas R; Pajares Garcia JM; Mate-Jimenez J
Hepatogastroenterology; 1999; 46(28):2265-8. PubMed ID: 10521978
[TBL] [Abstract][Full Text] [Related]
9. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.
Hinterleitner TA; Petritsch W; Aichbichler B; Fickert P; Ranner G; Krejs GJ
Z Gastroenterol; 1997 Aug; 35(8):603-8. PubMed ID: 9297775
[TBL] [Abstract][Full Text] [Related]
10. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine for induction of remission in Crohn's disease.
McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
[TBL] [Abstract][Full Text] [Related]
12. Oral butyrate for mildly to moderately active Crohn's disease.
Di Sabatino A; Morera R; Ciccocioppo R; Cazzola P; Gotti S; Tinozzi FP; Tinozzi S; Corazza GR
Aliment Pharmacol Ther; 2005 Nov; 22(9):789-94. PubMed ID: 16225487
[TBL] [Abstract][Full Text] [Related]
13. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
[TBL] [Abstract][Full Text] [Related]
14. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R
Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584
[TBL] [Abstract][Full Text] [Related]
15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
17. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial.
D'Haens G; Swijsen C; Noman M; Lemmens L; Ceuppens J; Agbahiwe H; Geboes K; Rutgeerts P
Am J Gastroenterol; 2001 Sep; 96(9):2564-8. PubMed ID: 11569676
[TBL] [Abstract][Full Text] [Related]
18. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
19. Intravenous cyclosporine for inflammatory bowel disease--safe and effective.
Chermesh I; Tamir A; Lachter J; Eliakim R
Hepatogastroenterology; 2007; 54(79):2003-6. PubMed ID: 18251148
[TBL] [Abstract][Full Text] [Related]
20. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach.
Margalit M; Israeli E; Shibolet O; Zigmond E; Klein A; Hemed N; Donegan JJ; Rabbani E; Goldin E; Ilan Y
Am J Gastroenterol; 2006 Mar; 101(3):561-8. PubMed ID: 16542292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]